What type of medicine is Talazoparib?

Talazoparib is a targeted anti-tumor drug that is a poly(ADP-ribose) polymerase (PARP) inhibitor. This type of drug blocks the repair function of PARP enzyme and interferes with the DNA repair process of cancer cells, thereby inducing tumor cell death. It is especially suitable for patients carrying BRCA1 or BRCA2 gene mutations, because such tumor cells themselves have defects in their DNA repair function and are more sensitive to PARP inhibition.

Talazoparib is used to treat certain types of breast and ovarian cancer. In Europe and the United States, the drug has been approved for the treatment of locally advanced or metastatic breast cancer with germline BRCA mutation and HER2-negative disease. Compared with other PARP inhibitors, talazoparib has a higher PARP trapping ability, that is, it can more effectively lock the PARP enzyme at the DNA break site, thereby further enhancing its killing power against cancer cells.

Clinical studies have shown that talazoparib has significant advantages in delaying tumor progression and improving progression-free survival. It is also convenient to take orally, making it easy for patients to use it for a long time. However, attention should also be paid to the possible adverse reactions caused by this drug, including anemia, neutropenia, nausea, fatigue, etc. Therefore, regular hematology tests are required during use, and the dose is adjusted according to the patient's tolerance if necessary.

Currently, talazoparib has not been officially launched in mainland China, and patients who need the medication usually need to obtain it through overseas medical channels. In some countries and regions, its generic version is also on the market, and the price is relatively affordable. For patients who meet the indications for medication, especially BRCA mutation-positive cancer patients, using talazoparib under the guidance of a doctor is expected to achieve more targeted therapeutic effects.

Reference materials:https://www.talzenna.com/